Evidence map›Paper›PMID 36167835›Full record

ArticleNature communications2022

Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades.

Raphaëlle Klitting, Liana E Kafetzopoulou, Wim Thiery, Gytis Dudas, Sophie Gryseels, Anjali Kotamarthi, Bram Vrancken, Karthik Gangavarapu, Mambu Momoh, John Demby Sandi and 17 more

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Sirtuin 1 Is Required for Optimal Mammarenavirus Multiplication.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Biological causes and impacts of rugged tree landscapes in phylodynamic inference.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Establishment of a Lassa Fever Specimen Biobank in Nigeria.The American journal of tropical medicine and hygiene · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Raphaëlle KlittingDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA. rklitting@scripps.edu.ORCID 0000-0002-7777-0308
Liana E KafetzopoulouDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, KU Leuven - University of Leuven, Leuven, Belgium.ORCID 0000-0003-4531-1374
Wim ThieryDepartment of Hydrology and Hydraulic Engineering, Vrije Universiteit Brussel, Brussels, Belgium.ORCID 0000-0002-5183-6145
Gytis DudasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0000-0002-0227-4158
Sophie GryseelsEvolutionary Ecology group, Department of Biology, University of Antwerp, 2610, Antwerp, Belgium.
Anjali KotamarthiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Bram VranckenDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, KU Leuven - University of Leuven, Leuven, Belgium.ORCID 0000-0001-6547-5283
Karthik GangavarapuDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Mambu MomohEastern Technical University of Sierra Leone, Kenema, Sierra Leone.
John Demby SandiViral Hemorrhagic Fever Program, Kenema Government Hospital, Ministry of Health and Sanitation, Kenema, Sierra Leone.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital, Ministry of Health and Sanitation, Kenema, Sierra Leone.
Foday AlhasanViral Hemorrhagic Fever Program, Kenema Government Hospital, Ministry of Health and Sanitation, Kenema, Sierra Leone.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Ministry of Health and Sanitation, Kenema, Sierra Leone.ORCID 0000-0002-4329-0795
Sylvanus OkogbeninIrrua Specialist Teaching Hospital, Irrua, Nigeria.
Ephraim Ogbaini-EmovoIrrua Specialist Teaching Hospital, Irrua, Nigeria.
Robert F GarryDepartment of Microbiology and Immunology, Tulane University, School of Medicine, New Orleans, LA, 70112, USA.ORCID 0000-0002-5683-3250
Allison R SmitherDepartment of Microbiology and Immunology, Tulane University, School of Medicine, New Orleans, LA, 70112, USA.
Mark ZellerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Matthias G PauthnerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-9212-4307
Michelle McGrawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Laura D HughesDepartment of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0003-1718-6676
Sophie DuraffourBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Stephan GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.ORCID 0000-0002-6562-0230
Marc A SuchardDepartment of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0001-9818-479X
Philippe LemeyDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, KU Leuven - University of Leuven, Leuven, Belgium.ORCID 0000-0003-2826-5353
Kristian G AndersenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Simon DellicourDepartment of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, KU Leuven - University of Leuven, Leuven, Belgium. simon.dellicour@ulb.be.ORCID 0000-0001-9558-1052

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
West African Emerging Infectious Disease Research Center (WA-EIDRC)U01AI151812 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD, GARRY, ROBERT F · 2020 to 2024
$13.2M
Tulane University COVID Antibody and Immunity Network (TUCAIN) SupplementU54CA260581 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ROBINSON, JAMES E · 2020 to 2024
$9.2M
Structure-based design of novel Lassa virus glycoproteins for vaccine developmentR01AI132244 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$6.5M
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktailR01AI132223 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$5.7M
Utilize Microbial Metagenomics for Viral Pathogen CharacterizationU54HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2017 to 2022
$5.5M
Statistical Innovation to Integrate Sequences and Phenotypes for Scalable Phylodynamic InferenceR01AI153044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Marc A. Suchard · 2021 to 2026
$2.4M
Boston Consortium to Cure SCD - Williams/Ellen GrantOT2HL152640 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI GRANT, PATRICIA ELLEN, WILLIAMS, DAVID A · 2019 to 2019
$88k
NCI NIH HHS U54 CA260581NHGRI NIH HHS U54 HG007480NHLBI NIH HHS OT2 HL152640NIAID NIH HHS R01 AI132223NIAID NIH HHS R01 AI132244NIAID NIH HHS R01 AI153044NIAID NIH HHS U01 AI151812NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790Wellcome TrustWellcome Trust 206298/Z/17/Z
6 · The paper itself

Abstract

Lassa fever is a severe viral hemorrhagic fever caused by a zoonotic virus that repeatedly spills over to humans from its rodent reservoirs. It is currently not known how climate and land use changes could affect the endemic area of this virus, currently limited to parts of West Africa. By exploring the environmental data associated with virus occurrence using ecological niche modelling, we show how temperature, precipitation and the presence of pastures determine ecological suitability for virus circulation. Based on projections of climate, land use, and population changes, we find that regions in Central and East Africa will likely become suitable for Lassa virus over the next decades and estimate that the total population living in ecological conditions that are suitable for Lassa virus circulation may drastically increase by 2070. By analysing geotagged viral genomes using spatially-explicit phylogeography and simulating virus dispersal, we find that in the event of Lassa virus being introduced into a new suitable region, its spread might remain spatially limited over the first decades.

Indexed as

Lassa FeverLassa virusAnimalsHumansPhylogeographyRisk FactorsRodentia

Identifiers

PMID36167835
PMCPMC9515147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.